Xencor (NASDAQ:XNCR) Price Target Raised to $37.00

Xencor (NASDAQ:XNCR – Free Report) had its price objective upped by JPMorgan Chase & Co. from $21.00 to $37.00 in a research note issued to investors on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on XNCR. Barclays set a $45.00 price objective on shares of Xencor and gave the company an “overweight” rating in a research note on Monday, October 26th. Wall Street Zen raised shares of Xencor from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Cantor Fitzgerald initiated coverage on shares of Xencor in a research note on Thursday, November 5th. They set an “overweight” rating and a $70.00 target price on the stock. Wedbush raised their price target on shares of Xencor from $30.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, October 27th. Finally, Bank of America lifted their price target on shares of Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Get Our Latest Stock Report on Xencor

Xencor Stock Performance

Shares of XNCR stock opened at $33.40 on Thursday. Xencor has a fifty-two week low of $10.38 and a fifty-two week high of $40.60. The stock has a 50 day simple moving average of $28.27 and a two-hundred day simple moving average of $18.65. The company has a market cap of $2.51 billion, a P/E ratio of -21.00 and a beta of 0.78.

Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.83. The firm had revenue of $116.52 million for the quarter, compared to analysts’ expectations of $63.00 million. Xencor had a negative return on equity of 21.28% and a negative net margin of 58.79%. The company’s revenue for the quarter was up 453.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) EPS. On average, research analysts predict that Xencor will post -2.61 earnings per share for the current year.

Insider Transactions at Xencor

In other Xencor news, Director Richard Ranieri sold 81,252 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $39.25, for a total value of $3,189,141.00. Following the transaction, the director owned 18,514 shares in the company, valued at approximately $726,674.50. This represents a 81.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.08% of the company’s stock.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Xencor during the second quarter valued at about $219,785,000. Primecap Management Co. CA bought a new stake in shares of Xencor during the second quarter worth about $163,919,000. Toronto Dominion Bank increased its position in shares of Xencor by 688.5% during the third quarter. Toronto Dominion Bank now owns 3,871,297 shares of the biopharmaceutical company’s stock worth $96,589,000 after acquiring an additional 3,380,297 shares in the last quarter. Jefferies Financial Group Inc. increased its position in shares of Xencor by 189.0% during the third quarter. Jefferies Financial Group Inc. now owns 2,082,243 shares of the biopharmaceutical company’s stock worth $51,952,000 after acquiring an additional 1,361,803 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Xencor during the second quarter worth about $17,568,000.

Xencor Company Profile

(Get Free Report)

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.

Further Reading

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.